Home > Insider Trading > Filing (0001567619-22-019388)

Filing Details

Accession Number:: 0001567619-22-019388
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-11-09 17:00:42
Reporting Period:: 2022-11-07

Accepted Time:: 2022-11-09 17:00:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1556270	Jay Jonathan Mazelsky	One Idexx Drive Westbrook ME 04092	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-11-07	24,002	$52.00	75,537	No	4	M	Direct
Common Stock	Disposition	2022-11-07	900	$378.60	74,637	No	4	S	Direct
Common Stock	Disposition	2022-11-07	2,000	$379.50	72,637	No	4	S	Direct
Common Stock	Disposition	2022-11-07	500	$380.85	72,137	No	4	S	Direct
Common Stock	Disposition	2022-11-07	3,704	$382.81	68,433	No	4	S	Direct
Common Stock	Disposition	2022-11-07	2,716	$383.29	65,717	No	4	S	Direct
Common Stock	Disposition	2022-11-07	3,018	$384.47	62,699	No	4	S	Direct
Common Stock	Disposition	2022-11-07	392	$385.01	62,307	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right-to-buy)	Disposition	2022-11-07	24,002	$0.00	24,002	$52.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2023-12-04	No	4	M	Direct

Footnotes

Includes 17 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2022
Represents the weighted average price of the shares sold ranging from a low of $377.99 to a high of $378.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $379.10 to a high of $380.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $380.68 to a high of $381.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $381.94 to a high of $382.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $382.95 to a high of $383.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $383.97 to a high of $384.935 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $384.98 to a high of $385.16 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Grant of option to buy 24,501 shares of Issuer common stock that became exercisable in five annual installments beginning December 5, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Not applicable.